136 related articles for article (PubMed ID: 15961983)
1. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients.
Mould DR; Zhang X; Nieforth K; Salgo M; Buss N; Patel IH
Clin Pharmacol Ther; 2005 Jun; 77(6):515-28. PubMed ID: 15961983
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships.
Soy D; Aweeka FT; Church JA; Cunningham CK; Palumbo P; Kosel BW; Sheiner LB;
Clin Pharmacol Ther; 2003 Dec; 74(6):569-80. PubMed ID: 14663459
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment.
Zhang X; Lin T; Bertasso A; Evans C; Dorr A; Kolis SJ; Salgo M; Patel I;
J Clin Pharmacol; 2007 Apr; 47(4):510-7. PubMed ID: 17389560
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients.
de Requena DG; Bonora S; Castagna A; Hasson H; Marucco DA; D'Avolio A; Sciandra M; Trentini L; Calcagno A; Lazzarin A; Di Perri G
J Antimicrob Chemother; 2008 Aug; 62(2):384-7. PubMed ID: 18487231
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy.
Bellibas SE; Siddique Z; Dorr A; Bertasso A; Sista P; Kolis SJ; Cotler S; Delora P;
Pediatr Infect Dis J; 2004 Dec; 23(12):1137-41. PubMed ID: 15626952
[TBL] [Abstract][Full Text] [Related]
6. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.
Ruxrungtham K; Boyd M; Bellibas SE; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH
J Clin Pharmacol; 2004 Jul; 44(7):793-803. PubMed ID: 15199084
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
Wheeler DA; Lalezari JP; Kilby JM; Wheat J; Delehanty J; DeMasi R; Patel I; Salgo M
J Clin Virol; 2004 Jun; 30(2):183-90. PubMed ID: 15125875
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.
Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A;
Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
Thompson M; DeJesus E; Richmond G; Wheeler D; Flaherty J; Piliero P; True A; Chiu YY; Zhang Y; McFalls E; Miralles GD; Patel IH
AIDS; 2006 Feb; 20(3):397-404. PubMed ID: 16439873
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition.
Zhang X; Nieforth K; Lang JM; Rouzier-Panis R; Reynes J; Dorr A; Kolis S; Stiles MR; Kinchelow T; Patel IH
Clin Pharmacol Ther; 2002 Jul; 72(1):10-9. PubMed ID: 12152000
[TBL] [Abstract][Full Text] [Related]
11. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide.
Boyd MA; Zhang X; Dorr A; Ruxrungtham K; Kolis S; Nieforth K; Kinchelow T; Buss N; Patel IH
J Clin Pharmacol; 2003 Dec; 43(12):1382-91. PubMed ID: 14615475
[TBL] [Abstract][Full Text] [Related]
12. [Enfuvirtide, first fusion inhibitor in the treatment of human immunodeficiency virus infection: mechanism of action and pharmacokinetics].
Raffi F
Med Mal Infect; 2004 Sep; 34 Spec No 1():3-7. PubMed ID: 15742549
[TBL] [Abstract][Full Text] [Related]
13. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
Fung HB; Guo Y
Clin Ther; 2004 Mar; 26(3):352-78. PubMed ID: 15110129
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
15. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
Cooper DA; Lange JM
Lancet Infect Dis; 2004 Jul; 4(7):426-36. PubMed ID: 15219553
[TBL] [Abstract][Full Text] [Related]
16. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
[TBL] [Abstract][Full Text] [Related]
17. Enfuvirtide: from basic investigations to current clinical use.
Joly V; Jidar K; Tatay M; Yeni P
Expert Opin Pharmacother; 2010 Nov; 11(16):2701-13. PubMed ID: 20977403
[TBL] [Abstract][Full Text] [Related]
18. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.
Charpentier C; Jenabian MA; Piketty C; Karmochkine M; Tisserand P; Laureillard D; Bélec L; Si-Mohamed A; Weiss L
Scand J Infect Dis; 2011 May; 43(5):373-9. PubMed ID: 21341978
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor.
Mohanty U; Dixit NM
J Theor Biol; 2008 Apr; 251(3):541-51. PubMed ID: 18258267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]